Tyme Technologies : Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission

FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5

1. Name and Address of Reporting Person * Eckard Jonathan 2. Issuer Name and Ticker or Trading Symbol TYME TECHNOLOGIES, INC. [TYME] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) Chief Business Officer / (Last) (First) (Middle) C/O TYME TECHNOLOGIES, INC. , 1 PLUCKEMIN WAY - SUITE 103 3. Date of Earliest Transaction (Month/Day/Year) (Street) BEDMINSTER NJ 07921 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Join/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security	8. Price of Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership
Code	V	(A)	(D)	Date Exercisable	Expriation Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Director	10% Owner	Officer	Other
Eckard Jonathan C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER, NJ07921			Chief Business Officer

Signatures

By: /s/ Richard Cunningham as attorney-in-fact for Jonathan Eckard	2022-09-16
**Signature of Reporting Person	Date

Explanation of Responses:

(*)	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**)	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 21,910 shares of Syros common stock for $98.36 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
(2)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 6,573 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
(3)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 6,573 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
(4)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 16,244 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
(5)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 13,146 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
(6)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 18,886 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
(7)	This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.